SSRI-induced extrapyramidal side-effects and akathisia: Implications for treatment

Journal of Psychopharmacology

Volumn 12, Issue 2, 1998, Pages 192-214

  Lane, Roger M ^a  

^a PFIZER INC   (United States)

Author keywords

Akathisia; Basal ganglia; CYP2D6; Dopamine; Extrapyramidal side effects; Serotonin syndrome; SSRIs

Indexed keywords

CYTOCHROME P450; DOPAMINE RECEPTOR BLOCKING AGENT; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; SEROTONIN; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

AKATHISIA; BASAL GANGLION; DISEASE PREDISPOSITION; DOPAMINERGIC SYSTEM; DRUG ACCUMULATION; DRUG HALF LIFE; DRUG WITHDRAWAL; ENDOGENOUS DEPRESSION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MELANCHOLIA; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RECEPTOR AFFINITY; REVIEW; RISK; TITRIMETRY; WELLBEING;

AKATHISIA, DRUG-INDUCED; BASAL GANGLIA DISEASES; CHOLINERGIC ANTAGONISTS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RISK FACTORS; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS;

EID: 0031808720     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119801200212     Document Type: Review

References (255)

1. Adler L A, Angrist B M (1995) Paroxetine and akathisia. Biol Psychiat 37: 336-337
2. Adler L A, Peselow E, Rosenthal M, Angrist B (1993) A controlled comparison of the effects of propanolol, benztropine and placebo on akathisia: an interim analysis. Psychopharmac Bull 29: 283-286
3. Adverse Drug Reactions Advisory Committee (ADRAC) (1996) Movement disorders with selective serotonin reuptake inhibitors. Med J Aust 166: 259
4. al Adwani A (1995) Brain damage and tardive dyskinesia. Br J Psychiat 167: 410-1
5. Albert M L, Fledman R G, Willis A L (1974) The 'subcortica' dementia of progressive supranuclear palsy. J Neurol Neurosurg Psychiat 37: 121-130
6. Alderman J, Greenblatt D J, Allison J, Chung M, Harrison W (1994) Desipramine pharmacokinetics with serotonin reuptake inhibitors (SSRIs), paroxetine or sertraline. Neuropsychopharmacology 10 (Suppl.3): 263S
7. Alexander G E, DeLong M R, Strick P L (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 9: 357-381
8. 3H] GBR-12435 binding to cytochrome P450 in the human brain. J Neurochem 62: 342-348
9. Altshuler L L, Pierre J M, Ames D (1994) Sertraline and akathisia. J Clin Psychopharmac 14: 278-9
10. Ames D, Wirshing W C, Marder S R, Yuwiler A, Brammer G L, Midha K K, Van Putten T (1993) Adjunctive fluoxetine in haloperidol-stabilized schizophrenics (abstract). Neuropsychopharmacology 9 (Suppl. 2): 116S
11. Andreasson O A, MacEwan T, Gulbrandsen A-T, McCreadie R G, Steen V M (1997) Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology 131: 174-179
12. Armstrong M, Daly A K, Cholerton S, Bateman D N, Idle J R (1992) Mutant debrisoquine hydroxylation genes in Parkinsons disease. Lancet 339: 1017-1018
13. Armstrong M, Daly A K, Blennerhassett R, Ferrier N, Idle J R (1997) Antipsychotic drug-induced movement disorder in schizophrenics in relation to CYP2D6 genotype. Br J Psychiat 23-26
14. Arthur H, Dahl M-L, Siwers B, Sjoquist F (1995) Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmac 51: 211-216
15. Artigas F, Perez V, Alvarez E (1994) Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Archs Gen Psychiat 51: 248-251
16. Arya D K, Szabadi E (1994) Dyskinesia associated with fluvoxamine. J Clin Psychopharmac 13: 365-366
17. Austin M P, Mitchell P (1996) Melancholia as a neurological disorder. In Parker G, Hadzi-Pavlovic D, (eds), Melancholia. Cambridge University Press, Cambridge, pp. 223-236
18. Austin M P, Ross M, Murray C, O'Carroll R E, Ebmeier K P, Goodwin G M (1992) Cognitive function in major depression. J Affect Disorders 25: 21-30
19. Bacher N M, Ruskin P (1991) Addition of fluoxetine to treatment of schizophrenic patients. Am J Psychiat 148: 274-275
20. Baldassano C F, Truman C J, Nierenberg A, Ghaemi S N, Sachs G S (1996) Akathisia: a review and case report following paroxetine treatment. Comp Psychiat 37: 122-124
21. Bangs M E, Petti T A, Janus M-D (1994) Fluoxetine-induced memory impairment in an adolescent. J Am Acad Child Adolesc Psychiat 33: 1303-1306
22. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirer J (1985) Ecogenetics of Parkinsons disease: 4-hydroxylation of debrisoquine. Lancet ii: 1213-1216
23. Bastianetto S, Perrault G, Sanger D J (1995) Pharmacological evidence of the involvement of sigma sites in DTG-induced contralateral circling in rats. Neuropharmacology 34: 107-114
24. Bauer M, Hellweg R, Baumgartner A (1996) Fluoxetine-induced akathisia does not reappear after switch to paroxetine, J Clin Psychiat 57: 593-594
25. Baxter L R, Phelps M E, Mazziotta J C, et al. (1989) Cerebral metabolic rates for glucose in mood disorders studied with positron emission tomography with FDG. Archs Gen Psychiat 42: 441-442
26. Beasley C M (1994) Fluoxetine-dopaminergic interaction data. J Clin Psychiat 55: 77-78
27. Benazzi F (1996) Urinary retention with fluoxetine-haloperidol combination in a young patient. Can J Psychiat 41: 606-607
28. Berk M (1993) Paroxetine induces dystonia and parkinsonism in obsessive-compulsive disorder. Hum Psychopharmac 8: 444-445
29. Berkley R B (1990) Discussion of fluoxetine and suicidal tendencies. Am J Psychiat 147: 1572
30. Bertschy G, Vandel S (1998) Fluoxetine-related indifference and akathisia. A case report. Therapie 48: 158-159
31. Bisserbe J C, Lane R, Wiseman R (1996) Predictors of response to SSRIs in patients with major depression. Neuropsychopharmacol 16 (Suppl.3): 122
32. Black B, Uhde T W (1992) Acute dystonia and fluoxetine. J Clin Psychiat 53: 327
33. 3 receptor releases dopamine from rat striatal slice. Eur J Psychopharmac 155: 349-350
34. Blier P, Bergeron R (1995) Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmac 15: 217-222
35. Bodner R A, Lynch T, Lewis L, Kahn D (1995) Serotonin syndrome. Neurology 45: 219-223
36. Bolden-Watson C, Richelson E (1993) Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosoraes. Life Sci 52: 1023-1029
37. Botsaris S D, Sypek J M (1996) Paroxetine and tardive dyskinesia. J Clin Psychopharmac 3: 258-259
38. Bouchard R H, Pourcher E, Vincent P (1989) Fluoxetine and extra-pyramidal side effects. Am J Psychiat 146: 1352-1353
39. Boyer W F, Feighner J P (1991) Side effects of the selective serotonin re-uptake inhibitors. In Feighner J P, Boyer W F (eds), Selective serotonin re-uptake inhibitors. John Wiley, Chichester, pp. 133-152.
40. Braud W M, Barnes T R E, Gore S (1983) Clinical characteristics of akathisia - a systematic investigation of acute psychiatric inpatient admissions. Br J Psychiat 143: 139-150
41. Brewerton T D (1991) Fluoxetine induced suicidality, serotonin and seasonality. Biol Psychiat 30: 190-196
42. Brod T M (1989) Fluoxetine and extrapyramidal side effects. Am J Psychiat 146: 1352-1353
43. Brosen K (1990) Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 18: 220-239
44. Brown A, Gershon S (1993) Dopamine and depression. J Neural Transm Gen Sect 91: 75-109
45. Brown E S (1997) Extrapyramidal side effects with low-dose risperidone. Can J Psychiat 42: 325-326
46. Buchsbaum M S, Wu J, DeLisi L E, et al. (1986) Frontal cortex and basal ganglia metabolic rates assessed by PET with F-2 deoxyglucose in affective illness. J Affect Disord 10: 137-152
47. Budman C L, Bruun R D (1991) Persistent dyskinesia in a patient receiving fluoxetine. Am J Psychiat 148: 1403
48. Cain J W (1992) Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a 'therapeutic window'? J Clin Psychiat 53: 272-277
49. Caley C F, Friedman J H (1992) Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiat 53: 278-282
50. Caligiuri M P, Lohr J B, Jeste D V (1993) Parkinsonism in neuroleptic naive schizophrenic patients. Am J Psychiat 150: 1343-1348
51. Cantello R, Aguggia M, Gilli M, et al. (1989) Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the 'hedonic' dopamine synapse. J Neurol Neurosurg Psychiat 52: 724-731
52. Casey D E (1994) Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiat Scand 89 (Suppl. 380): 14-20
53. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, Kane J M, Alvir J, Lieberman J A (1995) Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiat 152: 1724-1729
54. Chen N-H, Reith MEA (1994) Effects of locally applied cocaine, lidocaine and various uptake blockers on monoamine transmission in the ventral tegmental area of freely moving rats: A microdialysis study on monoamine interrelationships. J Neurochemistry 63(5): 1701-1713
55. Chong S A (1995) Fluvoxamine and mandibular dystonia. Can J Psychiat 40: 430-431
56. Choo V (1995) Paroxetine and extrapyramidal reactions. Lancet 341: 624
57. Chouinard G, Sultan S (1992) A case of Parkinson's disease exacerbated by fluoxetine. Hum Psychopharmac 7: 63-66
58. Christensen R G, Byerly M J (1996) Mandibular dystonia associated with the combination of sertraline and metoclopramide. J Clin Psychiat 57: 596
59. Chung W S D, Chiu H F K (1996) Drug-induced akathisia revisited. Br J Clin Prac 50: 270-278
60. Coffey C E, Figiel G S, Djang W T, Weiner R D (1990) Subcortical hyperintesity on magnetic resonance imaging: a comparison of normal and depressed elderly subjects. American Journal of Psychiat 147: 187-189
61. Committee on Safety of Medicines (CSM) (1993) Dystonia and withdrawal symptoms with paroxetine (Seroxat). Curr Prob 19: 1
62. Cooper J A, Sagar H J, Jordan N, Harvey N S, Sullivan E V (1991) Cognitive impairment in early, untreated Parkinsons disease and its relationship to motor disability. Brain 114: 2095-2122
63. Coulter D M, Pillans P I (1995) Fluoxetine and extrapyramidal side effects. Am J Psychiat 152: 122-125
64. Cummings J L (1992) Depression and Parkinsons disease: a review. Am J Psychiat 149: 443-454
65. Daniel D G, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A, Shoaf S, Egam M, Elkashef, Liboff S, Linnoila M (1994) Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmac 14: 340-343
66. Daniel D G, Smith K, Hyde T, Egan M (1996) Neuroleptic-induced tardive dyskinesia. Am J Psychiat 153: 734
67. Danish University Antidepressant Group (DUAG) (1986) Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology (Berlin) 90: 131-138
68. Danish University Antidepressant Group (DUAG) (1990) Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 18: 289-299
69. D'Arcy P F (1993) Dystonia and withdrawal symptoms with paroxetine. Int Pharm J 7: 140
70. Daric C, Dollfus S, Mihout B, Omnient Y, Petit M (1993) Fluoxetine et symptomes extrapyramidaux. L'Encephale 19: 61-62
71. Dave M (1994) Fluoxetine associated dystonia. Am J Psychiat 151: 149
72. DeClerc G E, Ruimy P, Verdeau-Pailles J (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmac 9: 138-143
73. Deutsch A Y, Moghaddam B, Innis R B, Krystal J H, Aghajanian G K, Bunney B S, Charney D S (1991) Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4: 121-156
74. Dewey S L, Smith G S, Logan J, Brodie J D (1993) Modulation of central cholinergic activity by GABA and serotonin: PET studies with 11C-benztropine in primates. Neuropsychopharmacol 8: 371-376
75. Dewey S L, Smith G S, Logan J, Alexoff D, Ding Y S, King P, Pappas N, Brodie J D, Ashby C R Jr. (1995) Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo mecrodialysis. J Neurosci 15: 821-829
76. Dubovsky S L, Thomas M (1996) Tardive dyskinesia associated with fluoxetine. Psychiat Serv 47: 991-993
77. Dunner D L, Dunbar G C (1992) Optimal dose regimen for paroxetine. J Clin Psychiat 53 (Suppl. 2): 21-26
78. Durif F, Vidailhet M, Bonnet A M, Blin J, Agid Y (1993) Levadopa-induced dyskinesias are improved by fluoxetine. Neurology 45: 1855-1858
79. Dursun S M, Mathew V M, Reveley M A (1993) Toxic serotonin syndrome after fluoxetine plus carbamazepine. Lancet 342: 442
80. Dursun S M, Burke J G, Reveley M A (1993) Toxic serotonin syndrome or extrapyramidal side effects? Br J Psychiat 166: 401-402
81. Eberstein S, Adler L A, Angrist B (1996) Nefazodone and akathisia. Biol Psychiat 40: 798-799
82. Eisenhauer G, Jermain D M (1993) Fluoxetine and tics in an adolescent. Ann Pharmacother 27: 725-726
83. Ellison J M, Stanziani P (1993) SSRI-associated nocturnal bruxism in four patients. J Clin Psychiat 54: 432-434
84. Ereshefsky L (1996) Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmac 16 (Suppl. 2): 37S-53S
85. Fabre L F, Abuzzahab F S, Amin M, Claghorn J L, Mendels J, Petrie W M, Dube S, Small J G (1995) Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiat 38: 592-602
86. Faherty C, Earley B, Leonard B E (1996) Biochemical and behavioural effects of selective serotonin reuptake inhibitors following direct micro injection into the left red nucleus of the rat. J Psychopharmac 11: 53-58
87. Fallon B A, Liebowitz M R (1991) Fluoxetine and extrapyramidal symptoms in CNS lupus. J Clin Psychopharmac 11: 147-148
88. Feighner J P, Boyer W F, Tyler D L, et al. (1990) Adverse consequences of fluoxetine-MAOI combination therapy. Clin Psychiatr 51: 222-225
89. Fichtner C G, Jobe T H, Braun B G (1991) Does fluoxetine have a therapeutic window? Lancet 338: 520-521
90. Fishbain D A (1996) Fluoxetine and extrapyramidal side effects. Am J Psychiat 153: 449
91. Fishbain D A, Dominguez M, Goldberg M, Olsen E, Rosomoff, H (1992) Dyskinesia associated with fluoxetine use. Neuropsychiat, Neuropsychol Behavi Neurol 5: 97-100
92. Fitzgerald K, Healy D (1995) Dystonias and dyskinesias of the jaw associated with the use of the SSRIs. Hum Psychopharmac 10: 215-219
93. Fleischhacker W W (1991) Propranolol for fiuoxetine-induced akathisia. Biol Psychiat 30: 531-532
94. Fonne-Pfister R, Bargetzi M J A, Meyer U A (1987) MPTP the neurotoxin inducing Parkinsons disease, is a potent inhibitor of human and rat P450 enzymes (P450bufl, P450dbl) catalyzing debrisoquine 4-hydroxylation. Biochim Biophys Res Comm 148: 1144-1150
95. Fox G C, Ebeid S, Vincenti G (1997) Paroxetine-induced chorea. Br J Psychiat 170: 193
96. Fuxe K, Bolme P, Agnati L, et al. (1976) The effect of DL- and D-propranolol on central monoamine neurons: I. Studies on dopamine mechanisms. Neurosci Letts 3: 45-52
97. Gardier A M, Lepoul E, Trouvin J H, Chanut E, Dessalles D C, Jacquot C (1994) Changes in dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: relationship with brain concentrations of fluoxetine and norfluoxetine. Life Sci 54: PL51-56
98. Gelenberg A J, Bassuk E L, Schoonover S C (1997) The practitioner's guide to psychoactive drugs, 3rd edn Plenum Press, New York
99. George M S, Trimble M R (1993) Dystönie reaction associated with fluvoxamine. J Clin Psychopharmac 13: 220-221
100. Goff D C, Midha K K, Brotman A W, Waites M, Baldessarini R J (1991) Elevation of plasma concentrations of haloperidol after addition of fluoxetine. Am J Psychiat 148: 790-792
101. Goff D C, Midha K K, Sarid-Segal O, Hubbard J W, Amico E (1995) A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 117: 417-423
102. Goldberg J F, Sacks M H, Kocsis J H (1995) Attenuation of response to serotonin reuptake inhibitors. Am J Psychiat 152: 954
103. Goldstein J M, Litwin L C, Malick J B (1987a) Ritanserin increases spontaneous activity of A9 and A10 dopamine neurons. Fed Proc 46: 966
104. Goldstein J M, Litwin L C, Sutton E B, et al (1987b) Effects of ICI 169, 369, a selective 5-HT2 antagonist, in electrophysiological tests predictive of antipsychotic activity. Soc Neurosci Abstr 13: 1649
105. Goodwin F K, Sack R L (1974) Central dopamine function in affective illness: evidence from precursors, enzyme inhibitors, and studies of central dopamine turnover. In Usdin E (ed.), Neuropsychopharmacology of monoamines and their regulatory enzymes. Raven Press, New York 261-279
106. Gorman J M, Liebowitz M R, Fyer A J, Goetz D, Compeas R B, Fyer M R, Davies S O, Klein D F (1987) An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmac 7: 329-339
107. Gormley N, Watters L, Lawlor B A (1997) Extrapyramidal side-effects in elderly patients exposed to selective serotonin reuptake inhibitors. Human Psychopharmac: Clini Exp 12: 139-143
108. Grundlack A L, Largent B L, Snyder S H (1986) Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)-piperadine. J Neurosc 6: 1757-1770
109. Gudjonsson O, Sanz E, Alvan G, Aquilonius S-M, Reviriego J (1990) Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinsons disease. Br J Clin Pharmac 30: 301-302
110. Gupta S, Andreasen N C, Arndt S, Flaum M, Schultz S K, Hubbard W C, Smith M (1995) Neurological soft signs in neuroleptic-naive and neuroleptic-treated schizophrenic patients and in normal comparison subjects. Am J Psychiat 152: 191-196
111. Hale A S (1996) Recent advances in the treatment of depression. Br J Hosp Med 55: 193-186
112. Hamilton M S, Opler L A (1992) Akathisia, suicidality and fluoxetine. J Clin Psychiat 53: 401-406
113. Hammer R P, Margulies J E, Lynn A B, et al. (1993) Chronic fluoxetine treatment upregulates dopamine receptors in the mesolimbic forebrain of the rat. Depression 1: 82-87
114. Harms H H (1983) The antidepressant agents desipramine, fluoxetine, fluvoxamine and norzimelidine inhibit uptake of [3H] Noradrenaline and [3H] 5-Hydroxytryptamine in slices of human and rat cortical brain tissue. Brain Res 275: 99-104
115. Hawley C J, Quick S J, Ratnam S, Pattinson H A, McPhee S (1996) Safety and tolerability of combined treatment with moclobemide and SSRI: a systematic study of 50 patients. J Psychopharmaco 11: 187-192
116. Heiligenstein J H, Tollefson G D, Faries D E (1993) A double-blind trial of fluoxetine, 20mg, and placebo in out-patients with DSM-III-R major depression and melancholia. Int Clin Psychopharmac 8: 247-251
117. Hickie I, Scott E, Mitchell P, Wilhelm K, Austin M P, Bennett B (1995) Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biol Psychiat 37: 151-160
118. Hoaken P C S (1995) An alert to extrapyramidal side effects from SSRIs letter. Can J Psychiat 40: 51
119. Hofmann M. (1996) SSRI-induzierte Akathisie. Psychiat Prax 23: 143-144
120. Hopwood S E, Bogle S, Wildgust H J (1993) The combination of fluoxetine and lithium in clinical practice. Int Clin Psychopharmac 8: 311-313
121. Horrigan J P, Barnhill L J (1994) Paroxetine-pimozide drug interaction. J Am Acad Child Adolesc Psychiat 33: 1060-1061
122. Hughs H H, Stanford S C (1995) Lack of effect of a lesion of cortical nonadrenergic neurones on inhibition of synaptosomal [3H] nonadrenaline uptake by 5HT uptake inhibitions ex vivo. Br J Pharmac 116: 236P
123. Hyttel J (1993) Comparative pharmacology of selective serotonin re-uptake inhibitors (SSRIs). Nord J Psychiat 47 (Suppl. 30): 5-20
124. Insel T R, Roy B F, Cohen R M, et al. (1982) Possible development of the serotonin syndrome in man. Am J Psychiat 139: 954-955
125. Iyengar S, Dilworth V, Mick S J, Contrecras P C (1990) Sigma receptors modulate both A9 and A10 dopaminergic neurons in the rat brain: functional interactions with NMDA receptors. Brain Res 524: 322-326
126. Jacobs B L, Azmitia E C (1992) Structure and function of the brain serotonin system. Physiol Rev 72: 165-229
127. Jacobs B L, Fornal C A (1993) 5-HT and motor control: a hypothesis. Trends Neurosci 16: 346-352
128. 1c receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmac 231: 223-229
129. Jimenez F J, Tejeiro J, Martinez-Junquera G, Cabrera-Valdivia F, Alarcon J, Garcia-Albea E (1994) Parkinsonism exacerbated by paroxetine. Neurology 44: 2406
130. Jones-Fearing K B (1996) SSRI and EPS with fluoxetine. J Am Acad Child Adolesc Psychiat 35: 1107-1108
131. Jordan S, Kramer G, Zukas P K, et al. (1994) In vivo biogenic araine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse 18: 294-297
132. Ketai R (1993) Interaction between fluoxetine and neuroleptics. Am J Psychiat 150: 836-837
133. Klaassen T, Verhey F R J, Sneijders G H J M, Rozendaal N, de Vet H C W, van Praag H M (1995) Treatment of depression in Parkinson's disease: a meta-analysis. J Neuropsychiat 7: 281-286
134. Klee B, Kronig M H (1993) Case report of probable sertraline-induced akathisia. Am J Psychiat 150: 986-987
135. Koe B K, Weissman A, Welch W M, Browne R G (1983) Sertraline, 1S, 4S-N-Methyl-4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmac Exp Ther 226: 686-700
136. Korsgaard S, Gerlach J, Christensson E (1985) Behavioural aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmac 118: 245-252
137. Krishnan K R (1993) Neuroanatomic substrates of depression in the elderly. J Geriat Psychiat Neurol 1: 39-58
138. Krishnan K R R, McDonald W M, Escalone P R, Doraiswamy P M, Na C, Husain M M, Figiel G S, Boyko O B, Ellinwood E H, Nemeroff C B (1992) Magnetic resonance imaging of the caudate nuclei in depression: preliminary observations. Arch Gen Psychiat 49: 553-557
139. La Porta L D (1993) Sertraline-induced akathisia. J Clin Psychopharmac 13: 219-220
140. Lane R M (1996a) Withdrawal symptoms on discontinuation of SSRIs. J Serotonin Res 3: 75-83
141. Lane R M (1996b) Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors, Int Clin Psychopharmac 11 (Suppl. 5): 31-63
142. Lane R, Fischler B (1995) The serotonin syndrome: coadministration, discontinuation and washout periods for the selective serotonin reuptake inhibitors (SSRIs). J Serotonin Res 3: 171-180
143. Lane R, Baldwin D (1995) SSRI-induced serotonin syndrome. J Clin Psychopharmac 17: 208-221
144. Lane R M, Baldwin D, Preskorn S H (1995) The SSRIs: advantages, disadvantages and differences. J Psychopharmac 9: 163-178
145. Lappin R I, Auchincloss E L (1994) Treatment of serotonin syndrome with cyproheptadine. N Engl J Med 331: 1021-1022
146. Latimer P R, Ravindran A V Bernatchez J-P, Fournier J-P, Gojer J A, Barrat K, Buttars J (1996) A six month comparison of toleration and efficacy of sertraline and fluoxetine treatment of major depression. Eur Neuropsychopharmac 6 (Suppl. 3): 124
147. Lauritzen L, Odgaard K, Clemmesen L, Lunde M, Öhrstrom J, Black C, Bech P (1996) Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. Acta Psychiat Scand 94: 241-251
148. Lavin M R, Mendelowitz A, Block S H (1993) Adverse reaction to high-dose fluoxetine. J Clin Psychopharmac 13: 452-453
149. Lepine J P, Wiseman R L, Zhu G (1997) A double-blind efficacy and safety study of sertraline and clomipramine in severe major depression. [abstract] Eur Neuropsychopharmacol 6: 123
150. Levenson J L (1985) Neuroleptic malignant syndrome. Am J Psychiat 142: 1137-1145
151. Lewis C F, DeQuardo J R, Tandon R (1997) Dystonia associated with trazodone and sertraline. J Clin Psychopharmac 17: 64
152. Lipinski J F, Mallya G, Zimmerman P, Pope H G (1989) Fluoxetine induced akathisia: clinical and theoretical implications. J Clin Psychiat 50: 339-342
153. Llerena A, Alm C, Dahl M-L, et al. (1992) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 14: 92-7
154. Lock J D, Gwirtsman H E, Targ E F (1990) Possible adverse drug interactions between fluoxetine and other psychotropics. J Clin Psychopharmac 10: 383-384
155. Maany I, Dhopesh V (1990) Akathisia and fluoxetine. J Clin Psychiat 51: 210-212
156. Mackay F, Dunn N, Wilton L, Pearce G, Fremantle S, Mann R D (1997) A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies Epidemiol Drug Safety 6: 235-246
157. Malek-Ahmadi P, Allen S A (1995) Paroxetine-molindone interaction. J Clin Psychiat 56: 82-83
158. Malt U F (1995) Practical aspects of long-term treatment. Eur Neuropsychopharmac 5: 288-289
159. Mander A, McCausland M, Workland B, Flamer H, Christophidis N (1994) Fluoxetine-induced dyskinesia. Aust N Z J Psychiat 28: 328-330
160. Marchioni E, Perucca E, Soragna D, Bo P, Malaspina A, Ferrandi D, Albergati A, Savoldi F (1996) Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity. Neurology 46: 853
161. Marsden C D, Jenner P (1980) The pathophysiology of extrapyramidal side-effect of neuroleptic drugs. Psychol Med 10: 55-72
162. Matsumoto R R, Walker J M (1992) Iontophoretic effects of putative sigma ligands on rubral neurons in the rat. Brain Res Bull 29: 419-425
163. Maurice T, Hiramatsu M, Itoh J, Kameyama T, Hasegawa T, Nabeshima T (1994) Behavioural evidence for a modulating role of sigma ligands in memory process. I. Attenuation of dizocilpine (MK 801)-induced amnesia. Brain Res 647: 44-56
164. Mayeux R, Stern Y, Sano M, Williams J B W, Cote L (1988) Relationship of serotonin to depression in Parkinsons disease. Movement Disord 3: 237-244
165. McCance-Katz E F, Marek K L, Price L H (1992) Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 42: 1813-1814
166. McDougle C J, Goodman W K, Price L H (1994) Dopamine antagonists in tic-related and psychotic spectrum obsessive-compulsive disorder. J Clin Psychiat 55 (Suppl.): 24-31
167. Meara R J, Bhowmick B K, Hobson J P (1995) Treatment of depression in Parkinson's disease using sertraline. Poster presented at BAP/BNPA Summer Meeting, 16-19 July, Cambridge
168. Meco G, Bonifati V, Fabrizio E, Vanacore N (1994) Worsening of Parkinsonism with fluvoxamine-two cases. Hum Psychopharmac 9: 439-41
169. Medical Economics Data (1995) Prozac (fluoxetine maleate). In Physicians' desk reference, 49th edn. Medical Economics Data Production, Montvale, NJ, pp. 943-947
170. Meltzer H Y, Young M, Metz J, et al. (1979) Extrapyrarmdal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 45: 165-75
171. Mendez M F, Adams N L, Lewandoski K S (1989) Neurobehavioral changes associated with caudate lesions. Neurology 39: 349-354
172. Micheli F Pardal M F, Gatto M, Asconape J, Giannula R, Parera I C (1993) Bruxism secondary to chronic antidopaminergic drug exposure. Clin Neuropharmac 16: 315-323
173. Mills K C (1995) Serotonin syndrome. Am Fam Phys 52: 1475-1482
174. Muly E C, McDonald W, Steffens D, Book S (1993) Serotonin syndrome produced by a combination of fluoxetine and lithium. Am J Psychiat 150: 1565
175. Muramatsu M, Tamaki-Ohashi J, Usuki C, Araki H, Chaki S, Aihara H (1988) 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices. Eur J Pharmac 153: 89-95
176. Murphy D L, Mueller A E, Hill J L, Tolliver T J, Jacobsen F M (1989) Comparative anxiogenic, neuroendocrine and other physiologic effects of m-chlorophenylpiperazine given intravenously and orally to healthy volunteers. Psychopharmacology 98: 275-282
177. Narita N, Hashimoto K, Tomitaka S, Minabe Y, Yamazaki K (1996) Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 307: 117-119
178. Nauta H J W (1986) The relationship of the basal ganglia to the limbic system. In Vinken J, Bryn G W, Klawans H L (eds), Extra-pyramidal Disorders. Handbood of Clinical Neurology, Vol. 5. Elsevier Science Publishers, Amsterdam, pp. 19-31
179. Newhouse P, Ko G, Richter E (1996) Comparison of sertraline and fluoxetine in depressed geriatric outpatients: plasma levels and efficacy. Eur Neuropsychopharmac 6 (Suppl. 3): 35
180. Nisnik H B, Tyndale R F, Sallee F R, et al. (1990) The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. Archs Biochem Biophys 276: 424-432
181. Noveske F G, Hahn K R, Flynn R J (1989) Possible toxicity of combined fluoxetine and lithium. Am J Psychiat 146: 1515
182. Nutt D J, Lalies M D, Lione L A, Hudson A L (1997) Noradrenergic mechanisms in the prefrontal cortex. J Psychopharmac 11: 163-168
183. Olivera A A (1996) A case of paroxetine-induced akathisia. Biol Psychiat 39: 910
184. Olivera A A (1997) Sertraline and akathisia: spontaneous resolution. Biol Psychiat 41: 241-242
185. Opler L A (1994) Sertraline and akathisia. Am J Psychiat 151: 620-621
186. Orengo C A, Kunik M E, Molinari V, Workman R H (1996) The use and toleralility of fluoxetine in geropsychiatric inpatients. J Clin Psychiat 57: 12-16
187. Ozdemir V, Herrmann N, Walker S, Kalow W, Naranjo C A (1996) Paroxetine potentiates CNS side effects of perphenazine. Clin Pharmac Ther 59: 188
188. 3 mediated control of dopaminergic function. Psychopharmacology 112: S60-S67
189. 2c receptor. Psychopharmac 126: 234-240
190. Parker G, Hadzi-Pavlovic D, Boyce P (1996) Issues in classification: II. Classifying melancholia. In: Parker G, Hadzi-Pavlovic D (eds), Melancholia. Cambridge University Press, Cambridge, pp. 20-37
191. Perez V, Gilaberte I, Faries D, Alavarez E, Artigas F (1997) Randomized, double-blind, placebo controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349: 1594-1597
192. Pohl R, Yeragani V K, Balon R, et al. (1988) The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiat 49: 100-104
193. Pohl R, Yeragani V K, Ortiz A, et al. (1986) Response of tricyclicinduced jitteriness to a phenothiazine in two patients. J Clin Psychiat 47: 427
194. Pollock B G, Mulsant B H, Sweet R A, Rosen J, Altieri L P, Perel J M (1995) Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmac Bull 31: 327-333
195. Power A C, Cowen P J (1992) Fluoxetine and suicidal behaviour: some clinical and theoretical aspects of a controversy. Br J Psychiat 161: 735-741
196. Poyurovsky M, Meerovich I, Weizman A (1995a) Beneficial effect of low-dose mianserin in fluvoxamine-induced akathisia in OCD patients. Int Clin Psychopharmac 10: 111-114
197. Poyurovsky M, Kosov A, Halperin E, Enoch D, Schneidman M, Weizman A (1995b) Akathisia-like behavior following ECT, and its successful treatment with low-dose mianserin. Int Clin Psychopharmac 10: 257-260
198. Poyurovsky M, Kreinin A, Modai I, Weizman A (1995c) Lithium-induced akathisia responds to low-dose mianserin: case report. Int Clin Psychopharmac 10: 261-263
199. Preskorn S H, Alderman J, Chung M, Harrison W, Messig M, Harris S (1994) Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmac 14: 90-98
200. Preskorn S H, Magnus R D (1994) Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull 30: 251-259
201. Preskorn S H, Silkey B, Beber J, Dorey C (1991) Antidepressant response and plasma concentrations of fluoxetine. Ann Clin Psychiat 3: 147-151
202. Price J S, Waller P C, Wood S M (1996) A comparison of the postmarketing safety of four serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmac 42: 757-763
203. Radomski J W, Dursun S M, Reveley M A (1995) Toxic serotonin syndrome (TSS): an update and revised diagnostic criteria. J Psychopharmac 9 (Suppl. 2): A21
204. Rapport D J, Calabrese J R (1993) Tolerance to fluoxetine. J Clin Psychopharmac 13: 361
205. Reccoppa L, Welch W A, Ware M R (1990) Acute dystonia and fluoxetine. J Clin Psychiat 51: 487
206. Rogers D, Lees A J, Smith E, et al. (1987) Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness: an experimental study. Brain 110: 761-766
207. Romanelli F, Adler D A, Bungay K M (1996) Possible paroxetine-induced bruxism. Ann Pharmacotherap 30: 1246-1248
208. Rone L A, Ferrando S (1996) Serotonin reuptake inhibitor-related extrapyramidal side effects in two patients with cerebral palsy. Psychosomatics 37: 165-166
209. Roose S P, Classman A H, Attia E, Woodring S (1994) Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiat 151: 1735-1739
210. Rothschild A J, Locke C A (1991) Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiat 52: 491-493
211. Sachdev P (1995) The identification and management of drug-induced akathisia. Drugs 4: 28-46
212. Salloway S, Malloy P, Kohn R, Gillard E, Duffy J, Rogg J, Tung G, Richardson E, Thomas C, Westlake R (1996) MRI and neuropsychological differences in early- and late-life-onset geriatric depression. Neurology 46: 1567-1574
213. Salokangas R K R, Saarijärvi S, Taiminen T, Kallioniemi H, Lehto H, Niemi H, Tuominen J, Ahola V, Syvälahti E (1996) Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiat Scand 94: 175-180
214. Samuel R Z (1996) EPS with lithium. J Am Acad Child Adolesc Psychiat 32: 1078
215. Sandler N H (1996) Tardive dyskinesia associated with fluoxetine. J Clin Psychiat 57: 91
216. Sathananthan G L, Gerson S (1973) Imipramine withdrawal: an akathisia-like syndrome. Am J Psychiat 130: 1286-1287
217. Scheepers B D M, Rogers D G (1994) Dyskinesias following treatment with 5-HT reuptake inhibitors. J Psychopharmac 8: 258-260
218. Sechter D, Troy S (1997) Double-blind randomized comparative study of sertraline and fluoxetine in depressive outpatients. Biol Psychiatry 42: 2595
219. Settle E C (1993) Akathisia and sertraline. J Clin Psychiat 54: 321
220. Shihabuddin L, Rapport D (1994) Sertraline and extrapyramidal side effects. Am J Psychiat 151: 288
221. Silver H, Nassar A (1992) Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add on double blind, placebo-controlled study. Biol Psychiat 31: 698-704
222. Simons J A (1996) Fluoxetine in Parkinson's disease. Move Disord 11: 581-582
223. Singh R K, Grupta A K, Singh B (1995) Acute organic brain syndrome after fluoxetine treatment. Am J Psychiat 152: 295-296
224. Small G W, Hamilton H H, Bystritsky A, Meyers B S, Nemeroff C B, the Fluoxetine Collaborative Study Group (1995) Clinical rersponse prdictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Inte Psychogeriat 7 (Suppl): 41-53
225. Smith C A D, Gough A C, Leigh P N, Summers B A, Harding A E, Maranganore D M, Sturman S G, Schapira A H V, Williams A C, Spurr N K, Wolf C R (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339: 1375-1377
226. Sovner R, Wolfe J (1988) Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid. N Engl J Med 319: 1671
227. Starkstein S E, Robinson R G, Price T R (1987) Comparison of cortical and subcortical lesions in the production of post stroke mood disorder. Brain 110: 1045-1059
228. Starkstein S E, Preziosi T J, Berthier M L, Bolduc P L, Mayberg H S, Robinson R G (1989) Depression and cognitive impairment in Parkinson's disease. Brain 112: 1141-1153
229. Starkstein S E, Mayberg H S, Leiguardia R, Preziosi T J, Robinson R G (1992) A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiat 55: 377-382
230. Steiger M J, Lledo P, Quinn N P, Marsden C D, Turner P, Jenner P G. Debrisoquine hydroxylation in Parkinson's disease. Acta Neurol Scand 86: 159-164
231. Stein M H. (1991) Tardive dyskinesia in a patient taking haloperidol and fluoxetine. Am J Psychiat 148: 683
232. Steinbusch H W M (1981) Distribution of serotonin immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience 4: 557-618
233. Sternbach H (1991) The serotonin syndrome. Am J Psychiat 148: 705-713
234. Steur E N (1993) Increase of Parkinson disability after fluoxetine medication. Neurology 43: 211-213
235. Stoukides J A, Stoukides C A (1991) Extrapyramidal symptoms upon discontinuation of fluoxetine (letter). Am J Psychiat 148: 1263
236. Strouse T B, Salehmoghaddam S, Spar J E (1993) Acute delirium and parkinsonism in a buproprion-treated liver transplant recipient. J Clin Psychiat 54: 489-490
237. Sweet R A, Mulsant B H, Kunik M E, et al. (1993) Phenomenology and prevalence of neuroleptic-induced akathisia in late life. Am J Geriat Psychol 1: 136-145
238. Tan C H (1996) Fluvoxamine and akathisia. J Clin Psychopharmac 16: 334-335
239. Tanda G, Frau R, Di Chiara G (1996) Chronic desipramine and fluoxetine differentially affect extracellular dopamine levels in rat prefrontal cortex. Psychopharmacology 127: 83-87
240. Tassin J P, Stinus L, Simon H, et al. (1978) Relationship between the locomotor hyperactivity induced by A10 lesions and the destruction of the frontocortical dopaminergic innervation in the rat. Brain Res 141: 267-281
241. Tate J L (1989) Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiat 146: 399-400
242. Teicher M, Glod C, Cole J (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psvchiat 147: 207-210
243. Thakore J H, Berti C, Dinan T G. An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. Acta Psychiat Scand 94: 194-197
244. Thomas D R, Nelson D R, Johnson A M (1987) Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 93: 193-200
245. Tiihonen J, Kuoppamaki M, Nagren K, Bergman J, Kronen E, Syvalahti K, Hietala J (1996) Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology 126: 277-280
246. Tome M B, Isaac M T, Harte R, Holland C (1997) Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmac 12: 81-89
247. 2 and sigma binding sites in human brain in vitro. Eur Neuropsychopharmac, 5 (Suppl. 3): 281
248. Tyndale R F, Sunahara R, Inaba T, Kalow W, Gonzales F J, Hiznik H B (1991) Neuronal P450 IIDI (debnsoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic gene CYP2D6. Mol Pharmac 40: 63-68
249. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology (Berlin) 98: 45-50
250. Wernicke J F, Dunlop S R, Dornseif B E, Zerbe R L (1987) Fixed dose fluoxetine therapy for depression. Psychopharmac Bull 23: 164-168
251. Wiesel F A (1976) Effects of high dose propranolol treatment on dopamine and norepinephrine metabolism in regions of rat brain. Neurosci Letts 2: 35-38
252. Wong D T Y, Threlkeld P G, Robertson D W (1991) Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology 5: 43-47
253. 2 receptor. Br J Pharmac 110 (Suppl.) 102P
254. Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E (1996) Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiat 153: 1631-1633
255. Zubenko G S, Cohen B M, Lipinski J F (1987) Antidepressant-induced akathisia. J Clin Psychopharmac 7: 254-257